Search results
Innovent sells its share in CAR T-cell therapy to IASO Bio for 18% equity
Pharmaceutical Technology· 49 minutes agoGracell’s lead asset was dual BCMA and CD19 targeting CAR-T cell therapy, GC01F. The therapy is...
Gracell’s lead asset was dual BCMA and CD19 targeting CAR-T cell therapy, GC01F. The therapy is...